The Hormone Related Malignancies (HRM) Program members study cancers of the reproductive tract and breast, and research the role of hormones in establishing and maintaining these cancers, the progression of these cancers to hormone-independent states, and mechanisms contributing to metastasis. The goal is to prevent, diagnose, and treat these cancers more effectively. Members are engaged in translating their knowledge of these processes into biomarkers and therapeutic targets for cancer patients through clinical trials. Novel technologies and approaches developed by the program to address these areas include 1) animal models to study epithelial to mesenchymal transition (EMT), cancer stem cells, apoptosis, and the microenvironment's role in metastasis;and 2) functional genomic and high throughput screens to identify new drugs targeting novel pathways in HRM-related cancers. The HRM Program includes highly interactive basic researchers and clinicians that promote the translational nature of the research conducted. HRM has two focus groups: 1) Women's Cancers, and 2) Prostate Cancer. In the prior funding period HRM made several major contributions to the field including: 1) Demonstration that screening does not reduce 10-year prostate cancer mortality, shedding light on the controversy surrounding prostate cancer screening {New Eng J of Med);2) The identification of Six1 as a critical tumor and metastasis promoting factor (J Clin Invest), and development of a program to identify small molecules of the Six1/Eya complex as an anti-breast cancer strategy;3) Discovery that the pro-inflammatory involution microenvironment stimulates pregnancy-associated breast cancer, leading to a clinical trial of fish oil and celecoxib in women with newly diagnosed breast cancer;and 4) The contribution of new recommendations for using 5 alpha-reductase inhibitors for prostate cancer prevention based on pathological characteristics observed in tumors of the Prostate Cancer Prevention Trial (New Eng J of Med, J Natl Cancer Inst, and Cancer Prev Res). HRM has 29 full members in 9 Departments and 3 schools at UCD and Colorado State University (CSU). HRM researchers currently hold $3.8M direct costs in NCI grants and $7.4M direct costs in other cancer relevant grants. Since 2005, per capita cancer research funding has increased by 56% from $247K to $385K. HRM produced 435 cancer-related publications from 2005-2010. Of these, 115 (26%) were interprogrammatic; 63 (15%) were intra-programmatic;and 52 (12%) were both inter- and intra-programmatic. Thus, 230 (53%) of the total cancer-related publications by members of this program were collaborative.

Public Health Relevance

The Hormone Related Malignancies Program (HRM) fosters cancer-focused inter-disciplinary research among basic scientists, clinical researchers and epidemiologists who study cancers of the reproductive tract and breast The goal is to prevent, diagnose, and treat these cancers more effectively through the translation of lab-based discoveries into therapeutic targets.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-26
Application #
8616639
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
26
Fiscal Year
2014
Total Cost
$19,837
Indirect Cost
$8,440
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Ghosh, Moumita; Miller, York E; Nakachi, Ichiro et al. (2018) Exhaustion of Airway Basal Progenitor Cells in Early and Established Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 197:885-896
Helfrich, Barbara A; Gao, Dexiang; Bunn Jr, Paul A (2018) Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. Lung Cancer 118:148-154
Oweida, Ayman; Phan, Andy; Vancourt, Benjamin et al. (2018) Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. Thyroid 28:739-747
Gadalla, Shahinaz M; Wang, Tao; Loftus, David et al. (2018) No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. Bone Marrow Transplant 53:383-391
Conroy, Shannon M; Shariff-Marco, Salma; Yang, Juan et al. (2018) Characterizing the neighborhood obesogenic environment in the Multiethnic Cohort: a multi-level infrastructure for cancer health disparities research. Cancer Causes Control 29:167-183
Bagati, Archis; Bianchi-Smiraglia, Anna; Moparthy, Sudha et al. (2018) FOXQ1 controls the induced differentiation of melanocytic cells. Cell Death Differ 25:1040-1049
Gavin, Kathleen M; Kohrt, Wendy M; Klemm, Dwight J et al. (2018) Modulation of Energy Expenditure by Estrogens and Exercise in Women. Exerc Sport Sci Rev 46:232-239
Cao, Yu; Green, Katherine; Quattlebaum, Steve et al. (2018) Methylated genomic loci encoding microRNA as a biomarker panel in tissue and saliva for head and neck squamous cell carcinoma. Clin Epigenetics 10:43
Salmon, Loïc; Stull, Frederick; Sayle, Sabrina et al. (2018) The Mechanism of HdeA Unfolding and Chaperone Activation. J Mol Biol 430:33-40
Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60

Showing the most recent 10 out of 1634 publications